한글목차

약제 요약

VAC 18193은 얀센이 60세 이상 성인의 RSV 매개 하기도 질환을 예방하기 위해 연구 중인 예방적 RSV 시니어 백신입니다. 이 예방 RSV 시니어 백신 후보물질은 얀센의 아데노벡터 플랫폼(AdVac)의 고유한 특징을 활용하고 있습니다. 이 시험 중인 백신은 RSV 바이러스의 융합 단백질을 암호화하는 유전자를 항원으로 포함하고 있습니다.

Janssen은 성인 RSV 환자를 대상으로 하며, 2022년에 미국과 유럽에서 승인 신청을 시행할 예정입니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 호흡기세포융합바이러스(RSV)용 VAC 18193에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 VAC 18193의 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 VAC 18193 시장 평가

• RSV에서 VAC 18193의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장의 RSV용 VAC 18193의 시장 규모
• 시장 분석 : 국가별
  • 미국의 RSV용 VAC 18193의 시장 규모
  • 독일의 RSV용 VAC 18193의 시장 규모
  • 영국의 RSV용 VAC 18193의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"VAC 18193 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the VAC 18193 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VAC 18193 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAC 18193 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary:

VAC 18193 is Janssen's investigational prophylactic RSV senior vaccine, which is being investigated to prevent RSV-mediated lower respiratory tract disease in adults aged 60 or older. The prophylactic RSV senior vaccine candidate leverages unique features of Janssen's adenovector platform (AdVac). The investigational vaccine contains the gene encoding for the fusion protein of the RSV virus as an antigen.

The Company has planned submissions in US and Europe in 2022 for RSV in adult's patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VAC 18193 description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on VAC 18193 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VAC 18193 research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VAC 18193.
• The report contains forecasted sales of VAC 18193 for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for VAC 18193 in RSV.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VAC 18193 Analytical Perspective by DelveInsight

• In-depth VAC 18193 Market Assessment

This report provides a detailed market assessment of VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• VAC 18193 Clinical Assessment

The report provides the clinical trials information of VAC 18193 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAC 18193 dominance.
• Other emerging products for RSV are expected to give tough market competition to VAC 18193 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAC 18193 in RSV.
• Our in-depth analysis of the forecasted sales data of VAC 18193 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VAC 18193 in RSV.

Key Questions:

• What is the product type, route of administration and mechanism of action of VAC 18193?
• What is the clinical trial status of the study related to VAC 18193 in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAC 18193 development?
• What are the key designations that have been granted to VAC 18193 for RSV?
• What is the forecasted market scenario of VAC 18193 for RSV?
• What are the forecasted sales of VAC 18193 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VAC 18193 for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

Table of Contents

1. Report Introduction

2. VAC 18193 Overview in RSV

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. VAC 18193 Market Assessment

• 5.1. Market Outlook of VAC 18193 in RSV
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of VAC 18193 in the 7MM for RSV
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of VAC 18193 in the United States for RSV
  • 5.3.2. Market Size of VAC 18193 in Germany for RSV
  • 5.3.3. Market Size of VAC 18193 in France for RSV
  • 5.3.4. Market Size of VAC 18193 in Italy for RSV
  • 5.3.5. Market Size of VAC 18193 in Spain for RSV
  • 5.3.6. Market Size of VAC 18193 in the United Kingdom for RSV
  • 5.3.7. Market Size of VAC 18193 in Japan for RSV

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options